CN114845731A - 针对包含pnag的微生物提供连续治疗的方法 - Google Patents

针对包含pnag的微生物提供连续治疗的方法 Download PDF

Info

Publication number
CN114845731A
CN114845731A CN202080083265.6A CN202080083265A CN114845731A CN 114845731 A CN114845731 A CN 114845731A CN 202080083265 A CN202080083265 A CN 202080083265A CN 114845731 A CN114845731 A CN 114845731A
Authority
CN
China
Prior art keywords
vaccine
formula
charged
reactor
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080083265.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·威安德
G·F·斯维士
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alopercy Ltd
Original Assignee
Alopercy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alopercy Ltd filed Critical Alopercy Ltd
Publication of CN114845731A publication Critical patent/CN114845731A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080083265.6A 2019-11-22 2020-11-20 针对包含pnag的微生物提供连续治疗的方法 Pending CN114845731A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962939331P 2019-11-22 2019-11-22
US62/939,331 2019-11-22
US202062994130P 2020-03-24 2020-03-24
US62/994,130 2020-03-24
PCT/US2020/061594 WO2021102320A1 (en) 2019-11-22 2020-11-20 Methods for providing continuous therapy against pnag comprising microbes

Publications (1)

Publication Number Publication Date
CN114845731A true CN114845731A (zh) 2022-08-02

Family

ID=75980043

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080083265.6A Pending CN114845731A (zh) 2019-11-22 2020-11-20 针对包含pnag的微生物提供连续治疗的方法

Country Status (11)

Country Link
US (1) US20230053458A1 (enExample)
EP (1) EP4061411A4 (enExample)
JP (2) JP2023502276A (enExample)
KR (1) KR20220107001A (enExample)
CN (1) CN114845731A (enExample)
AU (1) AU2020386971A1 (enExample)
BR (1) BR112022009924A2 (enExample)
CA (1) CA3162238A1 (enExample)
IL (1) IL293091A (enExample)
WO (1) WO2021102320A1 (enExample)
ZA (1) ZA202205546B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3152520A1 (en) * 2019-08-27 2021-03-04 OneBioPharma, Inc. Antimicrobial vaccine compositions
US11173199B2 (en) * 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
WO2023173020A1 (en) * 2022-03-11 2023-09-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody materials and methods targeting microbial polysaccharides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010011284A2 (en) * 2008-07-21 2010-01-28 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
WO2012145626A1 (en) * 2011-04-22 2012-10-26 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphylococcus vaccine
WO2013169657A1 (en) * 2012-05-07 2013-11-14 Sanofi Methods for preventing biofilm formation
WO2013181348A1 (en) * 2012-05-30 2013-12-05 The Brigham And Women's Hospital, Inc. Polysaccharide compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2415358T3 (es) * 2004-04-21 2013-07-25 The Brigham And Women's Hospital, Inc. Péptidos de fijación a la poli-N-acetil glucosamina (PNAG/DPNAG) y procedimientos para el uso de los mismos
US20130116423A1 (en) * 2010-04-23 2013-05-09 A. Stewart Campbell Synthetic Oligosaccharides for Staphylococcus Vaccine
US20150086601A1 (en) * 2012-05-07 2015-03-26 Sanofi Methods for preventing biofilm formation
US10828360B1 (en) * 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010011284A2 (en) * 2008-07-21 2010-01-28 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
WO2012145626A1 (en) * 2011-04-22 2012-10-26 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphylococcus vaccine
WO2013169657A1 (en) * 2012-05-07 2013-11-14 Sanofi Methods for preventing biofilm formation
WO2013181348A1 (en) * 2012-05-30 2013-12-05 The Brigham And Women's Hospital, Inc. Polysaccharide compositions and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAROLINE SOLIMAN 等: "Structural basis for antibody targeting of the broadly expressed microbial polysaccharide poly-N-acetylglucosamine", 《JOURNAL OF BIOLOGICAL CHEMISTRY》, vol. 293, no. 14, 15 February 2018 (2018-02-15), pages 5079 - 5089, XP055730365, DOI: 10.1074/jbc.RA117.001170 *
DAVID SKURNIK等: "The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG", 《EXPERT REVIEW OF VACCINES》, vol. 15, no. 8, 16 March 2016 (2016-03-16), pages 1041 - 1053, XP055345408, DOI: 10.1586/14760584.2016.1159135 *
M.L.GENING等: "Synthetic-(1-6)-Linked N-Acetylated and Nonacetylated Oligoglucosamines Used To Produce Conjugate Vaccines for Bacterial Pathogens", 《INFECTION AND IMMUNITY》, vol. 78, no. 2, 1 February 2010 (2010-02-01), pages 764 - 772, XP055006302, DOI: 10.1128/IAI.01093-09 *

Also Published As

Publication number Publication date
JP2026016535A (ja) 2026-02-03
BR112022009924A2 (pt) 2022-08-09
WO2021102320A1 (en) 2021-05-27
JP2023502276A (ja) 2023-01-23
ZA202205546B (en) 2023-05-31
US20230053458A1 (en) 2023-02-23
CA3162238A1 (en) 2021-05-27
KR20220107001A (ko) 2022-08-01
EP4061411A1 (en) 2022-09-28
IL293091A (en) 2022-07-01
EP4061411A4 (en) 2023-11-29
AU2020386971A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
AU750701B2 (en) Alpha-O-linked glycoconjugates, methods of preparation and uses thereof
AU758097B2 (en) Trimeric antigenic O-linked glycopeptide conjugates, methods of preparation and uses thereof
KR102713536B1 (ko) 클렙시엘라 뉴모니아에 대한 백신
JP2026016535A (ja) Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法
JP2026021461A (ja) 低汚染抗菌ワクチン
US10828360B1 (en) Methods for inhibiting biofilm formation
JP2025148346A (ja) 抗菌性ワクチン組成物
HK40077830A (en) Methods for providing continuous therapy against pnag comprising microbes
KR102803369B1 (ko) 클로스트리듐 디피실에 대한 안정성 백신
HK40078447A (en) Low contaminant antimicrobial vaccines
HK40076154A (en) Antimicrobial vaccine compositions
CA2126341A1 (en) Lipid-a analogs: new monosaccharide and dissaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
KR20250096768A (ko) 클렙시엘라 뉴모니아에의 백신
Lewicky Synthesis of novel Lipid A analogs as potential ligands for toll-like receptor 4
Bartholomew Studies Directed Towards the Synthesis of Immunologically Relevant Carbohydrates

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40077830

Country of ref document: HK